Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst

Indication
Central Line Associated Blood Stream Infections (CLABSI)

Other upcoming events for CRMD

Patent ExpiryPatent/Exclusivity Expiry: REZZAYO
Patent ExpiryPatent/Exclusivity Expiry: DEFENCATH

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonst — CRMD Phase 3 Readout | BioSniper